Azienda Ospedaliera di Padova
- Address
- lock Available on a paid plan
Azienda Ospedaliera di Padova - Comprehensive Clinical Research Center
Azienda Ospedaliera di Padova is a leading Italian academic medical center conducting advanced clinical research across multiple therapeutic areas. The institution demonstrates particular expertise in hematologic malignancies and rare disease research, with significant involvement in innovative immunotherapy and targeted therapy trials.
- Hematologic malignancies including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and follicular lymphoma
- Rare diseases and genetic disorders including hereditary angioedema, sickle cell disease, phenylketonuria, and laminopathies
- Autoimmune and inflammatory conditions including rheumatoid arthritis, lupus nephritis, dermatomyositis, and polymyositis
- Complex chronic diseases including chronic kidney disease, atopic dermatitis, ulcerative colitis, Crohn's disease, and idiopathic pulmonary fibrosis
The center actively participates in cutting-edge Phase 2 and Phase 3 trials evaluating novel biologic agents, monoclonal antibodies, and gene therapies. Research initiatives span from targeted oncology treatments using combination immunotherapies to innovative approaches for orphan diseases and hereditary conditions. The institution's commitment to pediatric research is evident through trials in juvenile idiopathic arthritis, pediatric hemophilia, and rare childhood cancers. With expertise in both minimal residual disease monitoring and advanced biomarker-driven studies, Azienda Ospedaliera di Padova plays a crucial role in advancing precision medicine and personalized treatment strategies across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 30 therapeutic areas and 15 of 540 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 492 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 128 by active trials.
lock +127 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +74 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera di Padova
lock Showing 1 of 392 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 540 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 18 | Unknown | 2017-10-02 | 2026-06-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.